Antimicrobial agents for routine testing and reporting on fastidious organisms



Streptococcus spp.
Streptococcus spp.
Haemophilus spp.e
Viridans groupr
GROUP A PRIMARY Ampicilline,g
Erythromycina,n,q Trimethoprim - sulfamethoxazole Penicillin (oxacillin disk)k sulfamethoxazole Ampicillin-sulbactam ceftazidimee or GROUP Bb PRIMARY ceftriaxonee
Cefuroxime (parenteral) Chloramphenicole,n Chloramphenicoln Chloramphenicoln Chloramphenicoln Amoxicillin-clavulanic acidf Ciprofloxacin or SELECTIVELY
Cefuroxime (oral) Ciprofloxacin or levofloxacin or lomefloxacin or moxifloxacin or Antimicrobial Agents for Routine Testing and Reporting on Fastidious Organisms "Warning": The following antimicrobial agents should not be routinely reported for bacteria isolated from the CSF and
which are included in this document. These antimicrobial agents are not the the drugs of choice and may not be effective for
treating CSF infections caused by these organisms (i.e., the bacteria included in Tables 2A to 2L in CLSI M100):

agents administered by oral route only first- and second-generation cephalosporins (except cefuroxime parenteral) fluoroquinolones NOTE 1: Selection of the most appropriate antimicrobial agents to test and to report is a decision made best by each clinical
laboratory in consultation with the infectious disease practitioners and the pharmacy, as well as the pharmacy and therapeutics and
infection control committees of the medical staff. The lists for each organism group comprise agents of proven efficacy that show
acceptable in vitro test performance. Considerations in the assignment agents to Groups A, B, and, C include clinical efficacy,
prevalence of resistance, minimizing emergence of resistance, cost, FDA clinical indications for usage, and current consensus
recommendations for first-choice and alternative drugs, in addition to the specific comments in footnotes "b" and "c". Unexpected
resistance should be reported (eg, resistance of Enterobacteriaceae to carbapenems). Tests on selected agents may be useful for
infection-control purposes.
NOTE 2: The listing of drugs together in a single box designates clusters of agents for which interpretive results (susceptible,
intermediate, or resistant) and clinical efficacy are similar. Within each box, an "or" between agents designates those agents for which
cross-resistance and cross-susceptibility are nearly complete. This means combined major and very major errors are fewer than 3%
and minor errors are fewer than 10%, based on a large population of bacteria tested. In addition, to qualify for an "or", at least 100
strains with resistance to the agents in question must be tested and a result of "resistant" must be obtained with all agents for at least
95% of the strains. "Or" is also used for comparable antimicrobial agents when tested against organisms for which "susceptible-only"
interpretive criteria are provided (eg, cefotaxime or ceftriaxone with Haemophilus influenzae). Thus, results from one agent connected
by an "or" could be used to predict results for the other agent. For example, a non-ESBL-producing isolate of Enterobacteriaceae
susceptible to cefotaxime can be considered susceptible to ceftriaxone. The results obtained from testing cefotaxime would be
reported and a comment could be included on the report that the isolate is also susceptible to ceftriaxone. When no "or"
connects agents within a box, testing of one agent cannot be used to predict results for another either owing to discrepancies of
insufficient data.
Information in boldface type is considered tentative for one year.

General Comments
a. Susceptibility and resistance to azithromycin, clarithromycin, and dirithromycin can be predicted by testing erythromycin.
b. Group B represents agents that may warrant primary testing but which should be reported only selectively, such as when the
organism is resistant to agents of the same class in Group A. Other indications for reporting the result might include selected specimen
sources (e.g. third-generation cephalosporin for isolates of H. influenzae from cerebrospinal fluids or CSF); stated allergy or
intolerance, or failure to respond to an agent in Group A; polymicrobial infections; infections involving multiple sites with different
microorganisms; or reports to infection control as an epidemiologic aid.
c. Group C represents alternative or supplemental antimicrobial agents that may require testing in those situations that harbor endemic
or epidemic strains resistant to one or more of the primary drugs (especially in the same class, e.g. beta-lactams), or for the treatment
of unusual organisms, or reporting to infection control as an epidemiologic aid.
d. Organisms that are susceptible to tetracycline are also considered susceptible to doxycycline and minocycline.
Haemophilus spp.
e. Only results of testing with ampicillin, one of the third-generation cephalosporins, chloramphenicol, and meropenem should be
reported routinely with cerebrospinal fluid isolates of Haemophilus influenzae.
f. Amoxicillin/clavulanic acid, azithromycin, clarithromycin, lorcarbef, cefdinir, cefixime, cefpodoxime, cefuroxime and telithromycin
are oral agents that may be used as empiric therapy for respiratory tract infections due to Haemophilus spp. The results of
susceptibility tests with these antimicrobial agents are often not useful for management of individual patients. However, susceptibility
testing of Haemophilus spp. with these compounds may be appropriate for surveillance or epidemiologic studies.
g. The results of ampicillin susceptibility tests should be used to predict the activity of amoxicillin. The majority of isolates of H.
that are resistant to ampicillin and amoxicillin produce a TEM-type-beta-lactamase. In most cases a direct beta-lactamase
test can provide a rapid means of detecting ampicillin and amoxicillin resistance.
Antimicrobial Agents for Routine Testing and Reporting on Fastidious Organisms h. Clinical indications and relevant pathogens include bacterial meningitis and concurrent bacteremia in association with meningitis
caused by Haemophilus influenzae (beta-lactamase and non-beta-lactamase producing strains).
Neisseria gonorrhoeae

i. A beta-lactamase test will detect one form of penicillin resistance in N. gonorrhoeae and also may be used to provide epidemiologic
information. Strains with chromosomally mediated resistance can be detected only by additional susceptibility testing, such as the disk
diffusion method or the agar dilution MIC method.
Streptococcus pneumoniae

j. S. pneumoniae isolates susceptible to levofloxacin are predictably susceptible to gemifloxacin and moxifloxacin. However, S.
susceptible to gemifloxacin or moxifloxacin cannot be assumed to be susceptible to levofloxacin.

k. Penicillin and cefotaxime or ceftriaxone or meropenem should be tested by a reliable MIC method (such as that described in CLSI
document M7) and reported routinely with CSF isolates of S. pneumoniae. Such isolated should also be tested against vancomycin
using the MIC or disk method. With isolates form other sites, the oxacillin disk screening test may be used. If the oxacillin zone size is
<19mm, penicillin and cefotaxime or ceftriaxone or meropenem MICs should be determined.
l. Rx: Rifampin should not be used alone for antimicrobial therapy.
Streptococcus spp.
m. Rx: Penicillin- or ampicillin-intermediate isolates mat require combined therapy with an aminoglycoside for bactericidal action.
n. Not routinely reported on organisms isolated form the urinary tract.
o. Susceptibility testing of penicillins and other beta-lactams approved by FDA for treatment of Streptococcus pyogenes or
Streptococcus agalactiae is not necessary for clinical purposes and need not be done routinely, since as with vancomycin, resistant
strains have not been recognized. Interpretive criteria are provided for pharmaceutical development, epidemiology or monitoring for
emerging resistance. Any strain found to be intermediate or resistant should be referred to a reference laboratory confirmation.
p. Report against S. pyogenes.
q. Rx: Recommendations for intrapartum prophylaxis for Group B streptococci are penicillin or ampicillin. While cefazolin is
recommended for penicillin-allergic women at low risk for anaphylaxis, those at high risk for anaphylaxis may receive clindamycin or
erythromycin. Group B streptococci are susceptible to ampicillin, penicillin, and cefazolin, but may be resistant to clindamycin and/or
erythromycin. When a Group B Streptococcus is isolated from a pregnant woman with severe penicillin allergy (high risk for
anaphylaxis) clindamycin and erythromycin should be tested and reported.
r. For this table, the beta-hemolytic group includes the large-colony-forming pyogenic strains of streptococci with Group A (S.
), C, or G antigens and strains with Group B (S. agalactiae) antigen. Small-colony-forming beta-hemolytic strains with
Group A, C, F, or G antigens (S. anginosus, previously termed "S. milleri") are considered part of the viridans group, and interpretive
criteria for the viridans group should be used.
Performance Standards for Antimicrobial Susceptibility Testing; Informational Supplement, M100. 2009. Clinical Laboratory
Standards Institute (CLSI - formerly NCCLS), Wayne, PA.
For more information, please consult the most current CLSI document.
1430 West McCoy Lane, Santa Maria, CA 93455, USA Phone: (805) 346-2766 ext. 5658 Fax: (805) 346-2760 Website: Email: Distribution Centers: California · Washington · Utah · Arizona · Texas · Ohio The Hardy Diagnostics' manufacturing facility and quality management system is certified to ISO 13485. Copyright 1996 - 2009 by Hardy Diagnostics. All rights reserved. Antimicrobial Agents for Routine Testing and Reporting on Fastidious Organisms


Microsoft word - journnal

MEDICAL TERMS IN MY SISTER'S KEEPER MOVIE AND THEIR TRANSLATION IN THE INDONESIAN SUBTITLE TEXT Oktafiani Prima Sari. First Supervisor : Andy Bayu Nugroho, S.S., M.Hum. Second Supervisor : Rachmat Nurcahyo, M.A. Yogyakarta State University ABSTRACT This research aims 1) to describe the types of medical terms in My Sister's

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics Randomised clinical trial: comparison of two everolimus dosingschedules in patients with advanced hepatocellular carcinoma H.-S. Shiah*,†,‡, C.-Y. Chen†, C.-Y. Dai§, C.-F. Hsiao¶, Y.-J. Lin**, W.-C. Su†, J.-Y. Chang*,†, J. Whang-Peng*,††,P.-W. Lin**, J.-D. Huang‡‡,1 & L.-T. Chen*,†,§,‡‡,1 *National Institute of Cancer